Based on the Coloplast A/S stock forecast from 0 analysts, the average analyst target price for Coloplast A/S is not available over the next 12 months. Coloplast A/S’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Coloplast A/S is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Coloplast A/S’s stock price was EUR 126.25. Coloplast A/S’s stock price has changed by +2.64% over the past week, +1.77% over the past month and +21.28% over the last year.
No recent analyst target price found for Coloplast A/S
No recent average analyst rating found for Coloplast A/S
Company Overview Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark. Address: Holtedam 1-3, Humlebæk, Denmark, 3050 Read Less
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Ur...Read More
N/A
N/A
16,019
September
EUR
Germany
Adjusted Closing Price for Coloplast A/S (CBHD:XETRA)
Loading...
Unadjusted Closing Price for Coloplast A/S (CBHD:XETRA)
Frequently Asked Questions About Coloplast A/S (CBHD:XETRA) Stock
Stock Target Advisor's fundamental analysis for Coloplast A/S's stock is Slightly Bullish .
CBHD:XETRA stock's dividend yield is 2.23%.
Our analysis grades CBHD:XETRA stock's dividend yield at A+. This means that CBHD:XETRA stock's dividend yield is above 100% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this CBHD:XETRA may be a good dividend stock for its sector.
Unfortunately we do not have enough data on CBHD:XETRA's stock to indicate what its average analyst target is.
CBHD:XETRA stock's Price/Earning ratio is 42.80.
Our analysis grades CBHD:XETRA stock's Price / Earning ratio at F. This means that CBHD:XETRA stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this CBHD:XETRA may be a overvalued for its sector.
The last closing price of CBHD:XETRA's stock was EUR 126.25.
The most recent market capitalization for CBHD:XETRA is EUR 28.40B.
Unfortunately we do not have enough analyst data on CBHD:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Coloplast A/S's stock.
As per our most recent records Coloplast A/S has 16,019 Employees.
Sorry we do not have any infomation available on Coloplast A/S's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Coloplast A/S (CBHD:XETRA) Stock
Stock Target Advisor's fundamental analysis for Coloplast A/S's stock is Slightly Bullish .
CBHD:XETRA stock's dividend yield is 2.23%.
Our analysis grades CBHD:XETRA stock's dividend yield at A+. This means that CBHD:XETRA stock's dividend yield is above 100% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this CBHD:XETRA may be a good dividend stock for its sector.
Unfortunately we do not have enough data on CBHD:XETRA's stock to indicate what its average analyst target is.
CBHD:XETRA stock's Price/Earning ratio is 42.80.
Our analysis grades CBHD:XETRA stock's Price / Earning ratio at F. This means that CBHD:XETRA stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this CBHD:XETRA may be a overvalued for its sector.
The last closing price of CBHD:XETRA's stock was EUR 126.25.
The most recent market capitalization for CBHD:XETRA is EUR 28.40B.
Unfortunately we do not have enough analyst data on CBHD:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Coloplast A/S's stock.
As per our most recent records Coloplast A/S has 16,019 Employees.
Sorry we do not have any infomation available on Coloplast A/S's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CBHD:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
